Results 191 to 200 of about 958,890 (240)

JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease. [PDF]

Therap Adv Gastroenterol
Fousekis FS, Jefremow A, Katsanos KH, Neurath MF, Atreya R.   +4 more
europepmc   +1 more source

The Interplay Between Rheumatoid Arthritis and Chronic Kidney Disease: From Mechanisms to Treatment. [PDF]

J Clin Med
Ichinose K.
europepmc   +1 more source

Rapid Improvement of Refractory Cutaneous Hypereosinophilic Syndrome with Abrocitinib Plus Methylprednisolone: A Case Report. [PDF]

Clin Cosmet Investig Dermatol
Liao B, Li X, Qiu Q, Zhang J, Xu M, Wang X, Liu W, Long R.   +7 more
europepmc   +1 more source

Therapeutic potential of peptidomimetics of suppressors of cytokine signaling (SOCS) proteins in rheumatic disorders. [PDF]

Front Med (Lausanne)
Cugudda A, Marasco D.
europepmc   +1 more source

IL-6/GP130/JAK/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical Features: Protocol for a Retrospective Cross-Sectional Study.

JMIR Res Protoc
Mellenthin C, Schaller F, Vignot L, Peisl S, Vesce R, Esposito I, Gonelle-Gispert C, Schneider C, Adamina M, Bühler LH.   +9 more
europepmc   +1 more source

Jak żyć? Jak kochać? Jak gotować? : Jacob Cats i poradniki Złotego Wieku

, 2018
openaire   +1 more source

Hematologia i reumatologia - jak daleko, jak blisko

Reumatologia, 2004
openaire  

Some of the next articles are maybe not open access.

Related searches:

JAK inhibitors for rheumatoid arthritis

Expert Opinion on Investigational Drugs, 2023
Introduction JAK (Janus kinase) is a type of non-receptor tyrosine kinase that includes JAK1, JAK2, JAK3, and Tyk2. Currently, there are five JAK inhibitors approved for treating rheumatoid arthritis.
S. Kubo, S. Nakayamada, Yoshiya Tanaka
semanticscholar   +1 more source

Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients

Science
Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti–PD-1 (programmed cell death protein 1) immunotherapy ...
D. Mathew, M. Marmarelis, Caitlin Foley, Joshua M. Bauml, Darwin Ye, Reem Ghinnagow, S. Ngiow, Max Klapholz, Soyeong Jun, Zhaojun Zhang, Robert Zorc, Christiana W. Davis, M. Diehn, Josephine R. Giles, Alexander C. Huang, Wei-Ting Hwang, Nancy R. Zhang, A. Schoenfeld, Erica L. Carpenter, Corey J. Langer, E. Wherry, A. Minn   +21 more
semanticscholar   +1 more source